What Is the Difference Between IgG and IgM?

IgG and IgM are both antibodies your immune system makes to fight infections, but they differ in structure, timing, and function. IgM is the first antibody produced when you encounter a new pathogen, acting as a rapid-response alarm, while IgG arrives later, sticks around longer, and handles the bulk of long-term protection. Their physical shapes are strikingly different too: IgM assembles into massive star-shaped complexes with ten or more binding sites, whereas IgG circulates as a compact, single-unit molecule. These differences ripple outward into everything from how doctors interpret blood tests to why newborns rely on their mother’s immunity for the first months of life.

How They Are Built

The structural gap between IgM and IgG is enormous. IgG is a monomer, meaning it exists as a single Y-shaped protein with two arms, each tipped with one antigen-binding site. It is the most abundant antibody in human blood, making up roughly three-quarters of circulating immunoglobulin. IgM, by contrast, assembles into a pentamer or hexamer: five or six of those Y-shaped units linked together in a ring, giving the whole complex ten or twelve binding sites rather than just two.¹ That makes IgM about five to six times the molecular weight of IgG, one of the largest proteins your body routinely produces.

Holding the IgM pentamer together is a small protein called the J chain, which clips into the ring through chemical bonds and stabilizes the whole assembly.² IgG has no equivalent structure because it does not need one: as a single unit, it is inherently stable. The J chain also gives IgM an additional trick, enabling it to bind receptors that transport it across mucosal surfaces into saliva, tears, and the gut lining.

Why IgM Comes First and IgG Lasts Longer

When your body detects an unfamiliar virus or bacterium, B cells begin producing IgM within days. This is the default antibody: B cells express IgM on their surface before they have had time to refine or switch their output. If the threat persists, a process called class switching occurs inside the lymph nodes, where B cells genetically rearrange their antibody genes to start producing IgG instead. The switch typically happens over a week or two. During a second encounter with the same pathogen, the IgG response kicks in much faster because memory B cells are already primed and ready to go.

This timeline has a direct practical consequence. IgM levels spike early and then drop relatively quickly, often fading within weeks to a few months. IgG levels rise more slowly but persist for months or years, sometimes for a lifetime. The half-life of IgG in the bloodstream is around three weeks, much longer than IgM’s roughly five days. That durability is partly maintained by a recycling receptor called FcRn, which rescues IgG molecules from degradation inside cells and releases them back into circulation. IgM lacks a comparable salvage pathway, which is one reason it clears from the blood faster.

Avidity Versus Affinity

If you compare a single binding arm of IgM to a single binding arm of IgG targeting the same pathogen, IgG almost always grips the target more tightly. This is because IgG antibodies have been refined by rounds of mutation and selection inside germinal centers, honing their fit to a specific target. IgM, produced earlier and with less refinement, typically has lower affinity per binding site.

But IgM compensates with sheer numbers. Having ten or twelve binding sites means that even if each individual grip is weaker, the overall hold on a pathogen covered in repeating surface molecules can be fierce. This collective binding strength is called avidity, and in laboratory measurements IgM’s avidity for certain antigens has been estimated at roughly twenty times higher than IgG’s affinity for the same targets.³ That makes IgM excellent at latching onto bacteria or viruses whose surfaces are studded with repeating patterns, precisely the kind of threat you need neutralized before your immune system has had time to fine-tune its IgG response.

Activating Complement and Recruiting Other Defenses

One of the most consequential functional differences involves complement, a cascade of blood proteins that can punch holes in bacterial membranes and flag debris for cleanup. A single IgM pentamer is far more efficient at triggering the classical complement pathway than a single IgG molecule. The reason is geometric: complement activation requires multiple antibody units clustered close together on a target surface. IgG has to accumulate enough individual molecules side by side, which takes time and a critical mass of antibodies. IgM arrives pre-assembled, so one pentamer landing on a bacterium can immediately kick off the complement cascade.¹

IgG, meanwhile, excels at a different set of jobs that IgM handles poorly or not at all. IgG is recognized by Fc-gamma receptors on immune cells like macrophages and natural killer cells. When IgG coats a pathogen, these cells grab it through those receptors and either engulf it or destroy it directly.⁴ IgM does not engage Fc-gamma receptors in the same way, so its influence on cell-mediated killing is limited. In short, IgM is the complement specialist; IgG is the all-rounder.

Crossing the Placenta

Of all the antibody classes in the human body, only IgG crosses the placenta. This transfer is mediated by the same FcRn receptor that recycles IgG in the bloodstream: syncytiotrophoblast cells lining the placenta actively shuttle IgG from the mother’s blood into the fetal circulation.⁵ By the third trimester, fetal IgG levels can actually exceed the mother’s, giving the newborn a borrowed immune defense that lasts until the infant’s own immune system matures over the first several months of life.

IgM cannot make this crossing. Its pentameric bulk is too large, and it lacks the structural features that FcRn recognizes. When a blood test detects IgM antibodies in a newborn’s serum, the interpretation is significant: those IgM molecules were not inherited from the mother. The baby’s own immune system produced them, usually in response to an infection contracted in utero or during delivery. That distinction makes neonatal IgM a valuable diagnostic clue for congenital infections like toxoplasmosis, rubella, or cytomegalovirus.

What Blood Tests Are Actually Measuring

Doctors routinely test IgM and IgG levels to figure out whether an infection is new or old. The logic follows directly from the timing differences described above. If your blood shows high IgM against a particular pathogen and low or absent IgG, the infection is probably recent, within the past few days to weeks. If IgG is high and IgM has dropped off, the infection likely happened weeks to months ago, or you were vaccinated and your immune system retained the memory.

This framework was used extensively during the COVID-19 pandemic. In one study of confirmed cases, IgM detected infection with a sensitivity of about 88%, while IgG reached roughly 97% across the testing window.⁶ The same principle applies to Lyme disease, where IgM antibodies to the causative spirochete can be detected during the acute illness in roughly two-thirds of patients, with IgM or IgG positivity rising to over 90% within a few weeks of treatment.⁷

The pattern is reliable enough that a positive IgM with negative IgG is often interpreted as “active or very recent infection,” while a positive IgG alone suggests past exposure or immunity. But the pattern is not foolproof. IgM can sometimes linger for months in certain infections, and some individuals generate IgG very quickly. Lab results always need to be read alongside symptoms, exposure history, and sometimes repeat testing a few weeks later.

The Four Flavors of IgG

IgG is not one molecule but four subtypes: IgG1, IgG2, IgG3, and IgG4. They share the same basic Y-shaped architecture, but their hinge regions and portions of their constant domains differ enough to give each subtype distinct biological behavior.⁸ IgG1 and IgG3 are the strongest activators of complement and are best at engaging Fc-gamma receptors on immune cells. IgG2 tends to respond to polysaccharide antigens, like those on the capsules of certain bacteria. IgG4, the rarest subtype, is unusual in that it can exchange half-molecules with other IgG4 antibodies in the blood, creating hybrid molecules. IgG4 is also associated with chronic antigen exposure and allergic tolerance.

IgM has no equivalent subtype system. There is essentially one form of IgM heavy chain. This makes sense given IgM’s role as the first-responder antibody: it needs to be broadly reactive and quickly deployable, not fine-tuned for specific downstream tasks. The diversity that IgG achieves through subtypes, IgM achieves through polyvalency and structural flexibility.

Mucosal Surfaces and IgM as a Backup

Most discussions of mucosal immunity focus on IgA, the dominant antibody in saliva, tears, breast milk, and the gut lining. But IgM also plays a quiet supporting role at mucosal surfaces. In people who are selectively IgA-deficient, a condition affecting roughly one in several hundred individuals of European descent, secretory IgM often compensates well enough that many of these people never develop recurrent infections.⁹ The J chain that holds the IgM pentamer together is the same molecule that enables IgA transport across mucosal epithelial cells, so IgM can use much of the same transport machinery to reach mucosal surfaces when IgA is absent.

IgM as a Regulator of Autoimmunity

One of the more surprising findings in recent immunology is that IgM antibodies do not just fight infections. They also help regulate the body’s own immune responses, particularly by keeping IgG in check. Mice that were genetically engineered to lack secreted IgM developed elevated levels of IgG autoantibodies against their own DNA and histones, leading to more severe kidney disease and earlier death compared to controls that still had IgM.¹⁰ In other words, removing IgM made autoimmune disease worse, not better.

More recent work has begun to explain how this works. IgM autoantibodies called rheumatoid factors, which bind to the constant region of IgG, appear to play a dual role depending on their binding characteristics. High-affinity versions stabilize IgG, while low-affinity, broadly reactive versions promote its clearance. A disruption in the balance between these two populations may contribute to the onset and progression of autoimmune conditions like rheumatoid arthritis.¹¹ The sugar modifications on both IgM and IgG also matter: in arthritic mice and in people with rheumatoid arthritis, changes in the ratio of specific sugar residues on IgG and IgM correlated with disease activity in opposite directions.¹²

This line of research is still developing, but the implication is striking. Rather than viewing IgM simply as a primitive, early antibody that IgG replaces, the picture emerging is one where IgM serves as a natural brake on IgG-driven autoimmunity throughout life.

IgM-Based Therapies

Nearly all therapeutic antibodies on the market today are IgG molecules. Rituximab, trastuzumab, and dozens of other monoclonal antibodies are engineered IgG variants because IgG is easier to produce, more stable in storage, and better understood pharmacologically. But IgM’s superior complement activation is starting to attract attention as a therapeutic advantage in its own right.

In preclinical studies, an engineered IgM antibody targeting CD20, the same protein targeted by rituximab for B-cell lymphomas, showed faster and more potent complement-dependent killing of tumor cells compared to an equivalent IgG antibody. The IgM also proved more effective when target cells had low antigen density, when complement levels were low, or when the tumor cells expressed high levels of complement inhibitors, all common reasons IgG-based therapies lose effectiveness as resistance develops.¹³ The practical hurdles to IgM-based drugs are substantial, since the molecule’s size, shorter half-life, and manufacturing complexity all work against easy clinical use, but the early data suggest that IgM may carve out a niche where IgG-based treatments have hit their limits.

The Evolutionary Story

IgM is the oldest antibody class in vertebrate evolution. Every jawed vertebrate studied, from sharks to humans, produces IgM, making it a molecule that has been conserved for at least 500 million years.¹⁴ IgG, by contrast, is a mammalian innovation. Birds, reptiles, and amphibians do not have IgG; instead, they rely on a related molecule called IgY, which is considered the evolutionary ancestor of both mammalian IgG and IgE.¹⁵

That evolutionary timeline helps explain the functional division of labor. IgM’s role as a broad, fast, complement-driven first responder reflects its ancient origins in organisms that could not afford to wait for a refined antibody. IgG represents a later layer of sophistication, enabled by the evolution of class switching, germinal center reactions, and somatic hypermutation, mechanisms that allow the immune system to iterate toward higher precision over days and weeks. You can think of IgM as the immune system’s shotgun and IgG as its sniper rifle: different tools, both essential, deployed at different stages of the same fight.

Glycosylation and Its Consequences

Both IgG and IgM carry sugar chains attached to their protein backbones, but the complexity and extent of this glycosylation differs dramatically. IgG has a single N-linked glycosylation site on each heavy chain, and the composition of that sugar chain profoundly affects the antibody’s behavior. Removing a core sugar residue called fucose, for example, can increase IgG’s ability to trigger cell killing through natural killer cells by an order of magnitude. Adding sialic acid to the sugar chain tips IgG toward anti-inflammatory activity.

IgM carries about five N-linked glycosylation sites per heavy chain, modified by more complex sugar structures.¹⁶ The sheer number of glycosylation sites on IgM creates enormous potential for functional variation, but the field has mostly focused on IgG glycosylation because IgG dominates in serum concentration, therapeutic applications, and ease of analysis. As tools improve for studying larger, more complex glycoproteins, IgM glycosylation is likely to become a more active area of research, particularly given the emerging evidence that sugar modifications on IgM track with autoimmune disease activity.

When IgM Testing Gets Tricky

Lab tests for IgM are not as straightforward as they might seem. One persistent challenge is that IgM’s large, sticky structure makes it prone to nonspecific binding in immunoassays, which can generate false-positive results. This is especially problematic in tests for infections where a false positive can have serious consequences, like congenital rubella screening or measles surveillance. In a comparison of commercial IgM assays for measles, sensitivities ranged from about 83% to 92%, and specificities varied from about 87% to nearly 100% depending on the assay format used.¹⁷ Capture assays, which isolate IgM before testing for antigen specificity, tend to reduce false positives compared to indirect assays, but no single platform is perfect.

Another issue is that rheumatoid factor, an IgM antibody that binds IgG, can interfere with many serological tests. When rheumatoid factor is present in a patient’s serum, it can bind to the IgG reagents in the test and mimic a positive IgM result for infections the patient never had. Labs often pre-treat samples to remove rheumatoid factor before running IgM-specific tests, but not all labs do this routinely, and not all clinicians realize the issue exists. If you have ever received a puzzling positive IgM result for an infection that did not match your symptoms or exposure history, rheumatoid factor interference is one of the more common explanations.